nach oben

Erschienen in:

01.01.2025 | Patient Opinion

Hypermobile type Ehlers-Danlos syndrome and generalized hypermobile spectrum disorder treatment preferences – a cross-sectional survey of patients

verfasst von: Patricia Teran-Wodzinski, Ambuj Kumar

Erschienen in: Rheumatology International | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

We aimed to assess the typical experiences, desired outcomes, satisfaction with clinical and anticipated outcomes, and the importance of improvements for individuals with Hypermobile Ehlers-Danlos Syndrome (hEDS) and Generalized Hypermobility Spectrum Disorder (G-HSD). A cross-sectional survey was conducted among adults aged 18 and above with hEDS and G-HSD. The survey included the Patient-Centered Outcome Questionnaire and an adapted version addressing common concerns in these individuals. Descriptive statistics were used for analysis. The survey received 483 responses with an 82% completion rate. Most respondents were females (90%), aged 21–30 (30%), living in North America (76%), and diagnosed with hEDS (80%). Participants diagnosed with hEDS reported higher typical levels of pain compared to those diagnosed with G-HSD and higher expected levels of pain and interference with daily activities post-treatment (p < 0.05). The areas of most significant concern were pain, fatigue, interference with daily activities, and walking issues. Our findings revealed no differences in how individuals from both groups rated their treatment expectations, except for the usual pain level and the expected pain level and interference with daily activities post-treatment. Patients’ perspectives are essential for developing appropriate treatment plans and improving outcomes for this patient population. Our results will hopefully inform the development of new interventions to impact outcomes that matter to individuals with hEDS and G-HSD.

Nur mit Berechtigung zugänglich

Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazka H, Levy H (2017) Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C 175(1):48–69. https://doi.org/10.1002/ajmg.c.31538CrossRef

Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A (2017) A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C 175(1):148–157. https://doi.org/10.1002/ajmg.c.31539CrossRef

Aubry-Rozier B, Schwitzguebel A, Valerio F, Tanniger J, Paquier C, Berna C, Hügle T, Benaim C (2021) Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different? Rheumatol Int 41(10):1785–1794. https://doi.org/10.1007/s00296-021-04968-3CrossRefPubMedPubMedCentral

Rombaut L, Malfait F, Cools A, De Paepe A, Calders P (2010) Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers-Danlos syndrome hypermobility type. Disabil Rehabil 32(16):1339–1345. https://doi.org/10.3109/09638280903514739CrossRefPubMed

Voermans NC, Knoop H, Bleijenberg G, van Engelen BG (2010) Pain in Ehlers-Danlos syndrome is common, severe, and associated with functional impairment. J Pain Symptom Manag 40(3):370–378. https://doi.org/10.1016/j.jpainsymman.2009.12.026CrossRef

Voermans NC, Knoop H (2011) Both pain and fatigue are important possible determinants of disability in patients with the Ehlers-Danlos syndrome hypermobility type. Disabil Rehabil 33(8):706–707. https://doi.org/10.3109/09638288.2010.531373CrossRefPubMed

Checa A (2012) Severe cartilage damage of the knee joint in two young women with hypermobility. Rheumatol Int 32(11):3661–3664. https://doi.org/10.1007/s00296-011-2071-zCrossRefPubMed

Luder G, Aeberli D, Mueller Mebes C, Haupt-Bertschy B, Verra ML, Baeyens JP (2022) Correlation of muscle and bone parameters, daily function and participation in women with generalized joint hypermobility: a descriptive evaluation. J Musculoskel Neuronal Interact 22(1):15–26

Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C et al (2017) The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C 175(1):8–26. https://doi.org/10.1002/ajmg.c.31552CrossRef

10.

Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RA (2021) Hypermobile Ehlers-Danlos syndromes: complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dynamics: Official Publication Am Association Anatomists 250(3):318–344. https://doi.org/10.1002/dvdy.220CrossRef

11.

Engelbert RH, Juul-Kristensen B, Pacey V, de Wandele I, Smeenk S, Woinarosky N, Sabo S, Scheper MC, Russek L, Simmonds JV (2017) The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. Am J Med Genet C 175(1):158–167. https://doi.org/10.1002/ajmg.c.31545CrossRef

12.

Peterson B, Coda A, Pacey V, Hawke F (2018) Physical and mechanical therapies for lower limb symptoms in children with hypermobility spectrum disorder and Hypermobile Ehlers-Danlos Syndrome: a systematic review. J Foot Ankle Res 11:59. https://doi.org/10.1186/s13047-018-0302-1CrossRefPubMedPubMedCentral

13.

Reychler G, De Backer MM, Piraux E, Poncin W, Caty G (2021) Physical therapy treatment of Hypermobile Ehlers-Danlos syndrome: a systematic review. Am J Med Genet: A 185(10):2986–2994. https://doi.org/10.1002/ajmg.a.62393CrossRefPubMed

14.

Palmer S, Davey I, Oliver L, Preece A, Sowerby L, House S (2021) The effectiveness of conservative interventions for the management of syndromic hypermobility: a systematic literature review. Clin Rheumatol 40(3):1113–1129. https://doi.org/10.1007/s10067-020-05284-0CrossRefPubMed

15.

Garreth Brittain M, Flanagan S, Foreman L, Teran-Wodzinski P (2024) Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome: a scoping review. Disabil Rehabil 46(10):1936–1953. https://doi.org/10.1080/09638288.2023.2216028CrossRefPubMed

16.

Palmer S, Bridgeman K, Di Pierro I, Jones R, Phillips C, Wilson M (2019) The views of people with joint hypermobility syndrome on its impact, management and the use of patient-reported outcome measures. A thematic analysis of open-ended questionnaire responses. Musculoskelet Care 17(2):183–193. https://doi.org/10.1002/msc.1387CrossRef

17.

Estrella E, Frazier PA (2024) Healthcare experiences among adults with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder in the United States. Disabil Rehabil 46(4):731–740. https://doi.org/10.1080/09638288.2023.2176554CrossRefPubMed

18.

Zeppieri G, Jr, George SZ (2017) Patient-defined desired outcome, success criteria, and expectation in outpatient physical therapy: a longitudinal assessment. Health Qual Life Outcomes 15(1):29. https://doi.org/10.1186/s12955-017-0604-1CrossRefPubMedPubMedCentral

19.

O’Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, Price DD, Robinson ME (2010) Patient-centered perspective on treatment outcomes in chronic pain. Pain Med (Malden Mass) 11(1):6–15. https://doi.org/10.1111/j.1526-4637.2009.00685.xCrossRef

20.

Robinson ME, Brown JL, George SZ, Edwards PS, Atchison JW, Hirsh AT, Waxenberg LB, Wittmer V, Fillingim RB (2005) Multidimensional success criteria and expectations for treatment of chronic pain: the patient perspective. Pain Med (Malden Mass) 6(5):336–345. https://doi.org/10.1111/j.1526-4637.2005.00059.xCrossRef

21.

Wilson AT, George SZ, Bialosky JE (2019) Patient-defined outcomes for pain, fatigue, emotional distress, and interference with activities did not differ by age for individuals with musculoskeletal pain. Pain Rep 4(6):e798. https://doi.org/10.1097/PR9.0000000000000798CrossRefPubMed

22.

Teran-Wodzinski P, Kumar A (2023) Clinical characteristics of patients with hypermobile type Ehlers-Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey. Rheumatol Int 43(10):1935–1945. https://doi.org/10.1007/s00296-023-05378-3CrossRefPubMed

23.

Tinkle BT (2020) Symptomatic joint hypermobility. Best Pract Res Clin Rheumatol 34(3):101508. https://doi.org/10.1016/j.berh.2020.101508CrossRefPubMed

24.

Clark NL, Johnson M, Rangan A, Kottam L, Swainston K (2023) The biopsychosocial impact of hypermobility spectrum disorders in adults: a scoping review. Rheumatol Int 43(6):985–1014. https://doi.org/10.1007/s00296-023-05298-2CrossRefPubMedPubMedCentral

25.

Eysenbach G (2004) Improving the quality of web surveys: the Checklist for reporting results of internet E-Surveys (CHERRIES). J Med Internet Res 6(3):e34. https://doi.org/10.2196/jmir.6.3.e34CrossRefPubMedPubMedCentral

26.

Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, Huy NT, Marušić A, Paul CL, Kwok J, Karbwang J, de Waure C, Drummond FJ, Kizawa Y, Taal E, Vermeulen J, Lee GHM, Gyedu A, To G, Verra ML et al (2021) A Consensus-based checklist for reporting of Survey studies (CROSS). J Gen Intern Med 36(10):3179–3187. https://doi.org/10.1007/s11606-021-06737-1CrossRefPubMedPubMedCentral

27.

Gaur PS, Zimba O, Agarwal V, Gupta L (2020) Reporting Survey Based studies - a primer for authors. J Korean Med Sci 35(45):e398. https://doi.org/10.3346/jkms.2020.35.e398CrossRefPubMedPubMedCentral

28.

Demmler JC, Atkinson MD, Reinhold EJ, Choy E, Lyons RA, Brophy ST (2019) Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ open 9(11):e031365. https://doi.org/10.1136/bmjopen-2019-031365CrossRefPubMedPubMedCentral

29.

Russek LN, Errico DM (2016) Prevalence, injury rate and, symptom frequency in generalized joint laxity and joint hypermobility syndrome in a healthy college population. Clin Rheumatol 35(4):1029–1039. https://doi.org/10.1007/s10067-015-2951-9CrossRefPubMed

30.

Murphy M, Hollinghurst S, Cowlishaw S, Salisbury C (2018) Primary care outcomes Questionnaire: psychometric testing of a new instrument. Br J Gen Practice: J Royal Coll Gen Practitioners 68(671):e433–e440. https://doi.org/10.3399/bjgp18X695765CrossRef

31.

El-Daly I, Ibraheim H, Rajakulendran K, Culpan P, Bates P (2016) Are patient-reported outcome measures in orthopaedics easily read by patients? Clin Orthop Relat Res 474(1):246–255. https://doi.org/10.1007/s11999-015-4595-0CrossRefPubMed

32.

Santore RF, Gosey GM, Muldoon MP, Long AA, Healey RM (2020) Hypermobility Assessment in 1,004 adult patients presenting with Hip Pain: correlation with diagnoses and demographics. J Bone Joint Surg Am Vol 102(Suppl 2):27–33. https://doi.org/10.2106/JBJS.20.00060CrossRef

33.

Nicholson LL, Simmonds J, Pacey V, De Wandele I, Rombaut L, Williams CM, Chan C (2022) International perspectives on Joint Hypermobility: a synthesis of current science to Guide Clinical and Research directions. J Clin Rheumatology: Practical Rep Rheumatic Musculoskelet Dis 28(6):314–320. https://doi.org/10.1097/RHU.0000000000001864CrossRef

34.

Castori M, Camerota F, Celletti C, Grammatico P, Padua L (2010) Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet: A 152A(9):2406–2408. https://doi.org/10.1002/ajmg.a.33585CrossRefPubMed

35.

Wijnhoven HA, de Vet HC, Picavet HS (2006) Prevalence of musculoskeletal disorders is systematically higher in women than in men. Clin J Pain 22(8):717–724. https://doi.org/10.1097/01.ajp.0000210912.95664.53CrossRefPubMed

36.

Tinkle BT, Levy HP (2019) Symptomatic joint hypermobility: the Hypermobile type of Ehlers-Danlos Syndrome and the Hypermobility Spectrum disorders. Med Clin N Am 103(6):1021–1033. https://doi.org/10.1016/j.mcna.2019.08.002CrossRefPubMed

37.

Boonstra AM, Stewart RE, Köke AJ, Oosterwijk RF, Swaan JL, Schreurs KM, Schiphorst Preuper HR (2016) Cut-off points for mild, moderate, and severe Pain on the Numeric Rating Scale for Pain in patients with Chronic Musculoskeletal Pain: variability and influence of sex and Catastrophizing. Front Psychol 7:1466. https://doi.org/10.3389/fpsyg.2016.01466CrossRefPubMedPubMedCentral

38.

Smith SM, Dworkin RH, Turk DC, McDermott MP, Eccleston C, Farrar JT, Rowbotham MC, Bhagwagar Z, Burke LB, Cowan P, Ellenberg SS, Evans SR, Freeman R, Garrison LP, Iyengar S, Jadad A, Jensen MP, Junor R, Kamp C, Katz NP et al (2020) Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain 161(11):2446–2461. https://doi.org/10.1097/j.pain.0000000000001952CrossRefPubMedPubMedCentral

39.

Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P (2017) Chronic fatigue in Ehlers-Danlos syndrome-hypermobile type. Am J Med Genet C 175(1):175–180. https://doi.org/10.1002/ajmg.c.31542CrossRef

40.

Kalisch L, Hamonet C, Bourdon C, Montalescot L, de Cazotte C, Baeza-Velasco C (2020) Predictors of pain and mobility disability in the hypermobile Ehlers-Danlos syndrome. Disabil Rehabil 42(25):3679–3686. https://doi.org/10.1080/09638288.2019.1608595CrossRefPubMed

41.

Celletti C, Castori M, La Torre G, Camerota F (2013) Evaluation of kinesiophobia and its correlations with pain and fatigue in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. Biomed Res Int 2013:580460. https://doi.org/10.1155/2013/580460CrossRefPubMedPubMedCentral

42.

Celletti C, Galli M, Cimolin V, Castori M, Albertini G, Camerota F (2012) Relationship between fatigue and gait abnormality in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. Res Dev Disabil 33(6):1914–1918. https://doi.org/10.1016/j.ridd.2012.06.018CrossRefPubMed

43.

Alsiri N, Cramp M, Barnett S, Palmer S (2020) Gait biomechanics in joint hypermobility syndrome: a spatiotemporal, kinematic and kinetic analysis. Musculoskelet Care 18(3):301–314. https://doi.org/10.1002/msc.1461CrossRef

44.

Galli M, Cimolin V, Rigoldi C, Castori M, Celletti C, Albertini G, Camerota F (2011) Gait strategy in patients with Ehlers-Danlos syndrome hypermobility type: a kinematic and kinetic evaluation using 3D gait analysis. Res Dev Disabil 32(5):1663–1668. https://doi.org/10.1016/j.ridd.2011.02.018CrossRefPubMed

45.

Simonsen EB, Tegner H, Alkjær T, Larsen PK, Kristensen JH, Jensen BR, Remvig L, Juul-Kristensen B (2012) Gait analysis of adults with generalised joint hypermobility. Clin Biomech (Bristol Avon) 27(6):573–577. https://doi.org/10.1016/j.clinbiomech.2012.01.008CrossRefPubMed

46.

Schmid S, Luder G, Mueller Mebes C, Stettler M, Stutz U, Ziswiler HR, Radlinger L (2013) Neuromechanical gait adaptations in women with joint hypermobility–an exploratory study. Clin Biomech (Bristol Avon) 28(9–10):1020–1025. https://doi.org/10.1016/j.clinbiomech.2013.09.010CrossRefPubMed

47.

Robbins SM, Cossette-Levasseur M, Kikuchi K, Sarjeant J, Shiu YG, Azar C, Hazel EM (2020) Neuromuscular activation differences during gait in patients with Ehlers-Danlos syndrome and healthy adults. Arthritis Care Res 72(11):1653–1662. https://doi.org/10.1002/acr.24067CrossRef

48.

Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome-hypermobile type. Am J Med Genet C 175(1):168–174. https://doi.org/10.1002/ajmg.c.31543CrossRef

49.

Orozco-Beltran D, Sánchez-Molla M, Sanchez JJ, Mira JJ, ValCrònic Research Group (2017) Telemedicine in Primary Care for patients with chronic conditions: the ValCrònic Quasi-experimental Study. J Med Internet Res 19(12):e400. https://doi.org/10.2196/jmir.7677CrossRefPubMedPubMedCentral

50.

Rolstad S, Adler J, Rydén A (2011) Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 14(8):1101–1108. https://doi.org/10.1016/j.jval.2011.06.003CrossRef

Titel: Hypermobile type Ehlers-Danlos syndrome and generalized hypermobile spectrum disorder treatment preferences – a cross-sectional survey of patients
verfasst von: Patricia Teran-Wodzinski
Ambuj Kumar
Publikationsdatum: 01.01.2025
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 1/2025
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05782-3

Late-onset Systemic Lupus Erythematosus

Review

Temporomandibular joint septic arthritis: a report of thirteen cases and a systematic review of the literature

Case Based Review

Treatment of idiopathic granulomatous mastitis: a retrospective case series

Short Communication

Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study

Observational Research

Artificial intelligence-based cardiovascular/stroke risk stratification in women affected by autoimmune disorders: a narrative survey

Review

Evaluation of an e-self-management intervention (Happy Hands app) for hand osteoarthritis: Study protocol for a multicentre randomised controlled trial

Open Access
Protocols

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Therapiestopp bei älteren MS-Kranken kann sich lohnen

17.04.2025
AAN-Jahrestagung 2025
Nachrichten

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

17.04.2025
Supraventrikuläre Tachykardien
Nachrichten

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

17.04.2025
Ablationstherapie
Nachrichten

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hypermobile type Ehlers-Danlos syndrome and generalized hypermobile spectrum disorder treatment preferences – a cross-sectional survey of patients

Abstract

Weitere Artikel der Ausgabe 1/2025

Late-onset Systemic Lupus Erythematosus

Temporomandibular joint septic arthritis: a report of thirteen cases and a systematic review of the literature

Treatment of idiopathic granulomatous mastitis: a retrospective case series

Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study

Artificial intelligence-based cardiovascular/stroke risk stratification in women affected by autoimmune disorders: a narrative survey

Evaluation of an e-self-management intervention (Happy Hands app) for hand osteoarthritis: Study protocol for a multicentre randomised controlled trial

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Dank Nasenspray seltener in die Notaufnahme

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten